Start your free stem cell consultation with one of our team members Book consultation
Take the quiz
Introducing human® Peptides — Science that serves the people. Join waitlist

The details behind the science

Through rigorous research and scientific data we’ve built this brand on a foundation of knowledge.

The Evidence

Trial results, category by category

Musculoskeletal & Orthopedic

Rotator cuff repair, re-tear prevention

In a controlled study, adding mesenchymal cells at the tendon-bone interface during rotator cuff repair produced complete healing in 100% of patients at six months, versus 67% without. Ten years later, 87% of the cell-treated repairs remained intact, against 44% of the controls.
Hernigou et al., International Orthopaedics, 2014.

Degenerative disc disease, chronic low back pain

In a randomized trial of injectable discogenic cells for degenerative disc disease, patients in the high-dose group averaged nearly 63% less pain at one year, with significant gains in function and quality of life.
DiscGenics phase I/II trial, reported 2024.

Knee osteoarthritis, cartilage regrowth

In a randomized, double-blind trial, a single injection of adipose-derived mesenchymal cells produced significantly greater knee cartilage volume on MRI at 12 months than the comparison treatment, alongside significant improvement in pain, function, and quality of life.
Lu et al., Stem Cell Research & Therapy, 2019. NCT02162693.

Neurological & Neurodegenerative

Spinal cord injury, functional recovery

In a clinical trial of patients with spinal cord injury treated with their own bone-marrow mesenchymal cells, 75% showed measurable improvement in sensory, motor, and autonomic function. Among the least severely injured group, all patients improved.
Reported in Experimental and Therapeutic Medicine, 2013.

Traumatic brain injury, chronic motor deficits

In a randomized, sham-controlled phase 2 trial, patients with motor deficits persisting more than a year after brain injury showed significant improvement in motor function at 24 weeks after mesenchymal cell implantation, with continued gains at 48 weeks. The result met the standard for Class I evidence.
STEMTRA trial, Neurology, 2024. NCT02416492.

Ischemic stroke, motor recovery

In a randomized trial of patients recovering from stroke, those treated with their own mesenchymal cells showed significantly greater motor recovery than standard care alone, with imaging suggesting the cells aided sensorimotor rewiring in the brain.
Jaillard et al., Translational Stroke Research, 2020. NCT00875654.

Autoimmune & Inflammatory

Systemic lupus erythematosus, survival (MSC)

Across trials using umbilical-cord mesenchymal cells for treatment-resistant lupus, patients showed a 92.5% survival rate, a striking figure in a disease this severe, alongside reduced disease activity.
Reported in a comprehensive analysis of autoimmune stem cell trials, 2025.

Crohn's disease, remission (MSC, phase III)

In the phase III ADMIRE-CD trial, patients with treatment-resistant perianal fistulas from Crohn's disease reached combined remission at 52 weeks in 56.3% of the cell-treated group, versus 38.6% on placebo. The therapy went on to regulatory approval in Europe.
ADMIRE-CD trial (darvadstrocel), 2016. NCT01541579.

Crohn's disease, immune tolerance (Treg)

In a phase I/IIa trial, 20 patients with refractory Crohn's disease received a single infusion of antigen-specific regulatory T cells. The treatment was well tolerated and showed dose-related improvement, an early signal that Tregs can help restore immune tolerance.
Desreumaux et al., Gastroenterology, phase I/IIa Crohn's trial.

Autoimmune hepatitis, reducing immunosuppression (Treg)

In early-phase trials for autoimmune hepatitis, a chronic liver condition usually requiring lifelong immunosuppression, infusion of a patient's own expanded regulatory T cells was safe and showed potential to improve disease control while tapering off immunosuppressant drugs.
Reviewed in Frontiers in Immunology, 2026.

Organ Function & Metabolic Health

Type 2 diabetes, blood sugar control

In a double-blind, randomized, placebo-controlled trial, patients given umbilical-cord mesenchymal cells lowered their HbA1c by 1.31% over 48 weeks, versus 0.63% on placebo, and cut daily insulin use, with improved insulin sensitivity on formal testing.
Phase II UC-MSC trial, Stem Cell Research & Therapy, 2022.

Heart failure, pumping strength

In the C-CURE randomized trial, patients with chronic heart failure treated with cardiopoietic mesenchymal cells improved their ejection fraction from 27.5% to 34.5%, while the standard-care group barely changed, and walked 62 meters further in six minutes.
C-CURE trial, Journal of the American College of Cardiology, 2013.

Long COVID, lung recovery (3-year follow-up)

In a randomized, double-blind, placebo-controlled trial of patients with severe COVID-19, those who received mesenchymal cells showed better lung-lesion recovery, improved walking distance, and higher quality-of-life scores, with benefits still measurable three years later.
3-year follow-up RCT, Stem Cell Research & Therapy, 2025. NCT04288102. Peripheral artery disease, avoiding amputation
In patients with critical limb ischemia, the most severe form of peripheral artery disease, a meta-analysis of randomized trials found that cell therapy reduced the relative risk of amputation by 41%, alongside significant improvements in ulcer healing, new blood-vessel formation, and pain-free walking distance.
Meta-analysis of randomized trials in critical limb ischemia, 2018.

Degenerative Eye & Hearing

Retinitis pigmentosa, restoring vision (Wharton's jelly cells)

In a phase 3 trial using Wharton's jelly mesenchymal cells, the same tissue source SOMA uses, patients with retinitis pigmentosa improved their best-corrected visual acuity from an average of 70.5 to 80.6 letters over six months, with measurable gains in visual field, retinal thickness, and photoreceptor response.
Özmert and Arslan, Stem Cell Research & Therapy, 2020.

Retinitis pigmentosa, maintaining sight (intravenous)

In a phase I/II trial of intravenous umbilical-cord mesenchymal cells for advanced retinitis pigmentosa, 96.9% of patients maintained or improved their vision at three months, with no serious adverse effects across a full year of follow-up.
Zhao et al., 2020.

Retinitis pigmentosa, suprachoroidal delivery

In a clinical trial delivering mesenchymal cell spheroids to the eye, patients showed statistically significant visual-acuity improvement sustained through six months, the first study to show visual gains in RP patients who still had relatively good baseline vision.
Suprachoroidal MSC trial, Stem Cell Research & Therapy, 2023. Hearing loss and tinnitus, PRP and regenerative signaling
The inner ear has long been considered beyond repair. That is beginning to change. In a clinical series of 200 patients with sensorineural hearing loss treated with intratympanic platelet-rich plasma, delivered directly to the round window, 172 (86%) showed measurable hearing improvement across repeated treatments. The likely mechanism is growth-factor signaling, especially IGF-1: in a separate randomized trial of 120 patients, IGF-1 applied to the round window improved hearing in 66.7%, versus 53.6% with standard steroid treatment. Because the regenerative signaling in platelet-rich plasma overlaps substantially with the paracrine activity of stem cells, this points toward a shared regenerative pathway for a condition with few other options.
Intratympanic PRP series (Shim), Acta Scientific Otolaryngology; IGF-1 round-window RCT, Nakagawa et al.

Fertility (Female & Male)

Premature ovarian insufficiency, restoring fertility (umbilical-cord cells)

In a clinical study of 61 women with premature ovarian insufficiency treated with umbilical-cord mesenchymal cells injected into the ovary, treatment restored ovarian function, improved follicle development and egg collection, and led to four healthy live births.
Yan et al., Cell Proliferation, 2020.

Poor ovarian response, live births (menstrual-blood cells)

In a phase I/II trial of women who had responded poorly to conventional fertility treatment, intra-ovarian mesenchymal cell therapy produced natural conception in four women within three months and a 33% live-birth rate, outperforming standard IVF controls.
Zafardoust et al., Stem Cell Reviews and Reports, 2020.

Non-obstructive azoospermia, restoring sperm (male infertility)

In a phase I trial of 80 men with non-obstructive azoospermia, a form of male infertility long considered untreatable, injection of mesenchymal cells into the testicular network led to regeneration of the sperm-producing tubules and improved hormonal signaling.
BM-MSC azoospermia trial, 2024.

Erectile dysfunction, restoring function (diabetic ED)

In a phase 2 trial of men with diabetic erectile dysfunction unresponsive to standard medication, injection of mesenchymal cells produced significant, measurable improvement in erectile function and penile blood flow, sustained across the follow-up period.
Intracavernous BM-MSC trial, 2024.

Aesthetics: Skin & Hair

Hair restoration, hair count (androgenetic alopecia)

In a randomized controlled trial of mesenchymal-cell-derived exosomes for pattern hair loss, patients gained an average of 35 additional hairs per square centimeter over 12 weeks, with significant increases in hair density and thickness.
MSC exosome AGA trial, 2024.

Hair restoration, density and reduced shedding

In a phase I/II trial of placenta-derived mesenchymal-cell exosomes injected into the scalp, patients with androgenetic alopecia showed significant improvement in hair density and diameter alongside reduced hair loss.
Placental MSC exosome AGA trial, 2024.

Skin rejuvenation, brightness and texture (umbilical-cord cells)

In a randomized, split-face trial combining umbilical-cord mesenchymal-cell signaling factors with microneedling, the treated side showed significantly greater improvement in skin brightness, reduced wrinkles and pores, and increased elasticity than microneedling alone.
hUC-MSC conditioned media split-face RCT, 2022.

Skin rejuvenation, collagen and wrinkles

In a randomized, split-face trial of mesenchymal-cell exosomes applied with microneedling for facial aging, treatment produced significant reductions in wrinkle depth and pigmentation, with skin biopsies confirming increased collagen density.
MSC exosome facial aging split-face RCT, 2025.

Donor Protocol

Every batch is tested, and you’re handed the results before treatment.

Before any therapy is given to you, the exact cells you will receive go through one of the most thorough screening panels in the field, in the cleanest ISO-rated stem cell laboratory in North America. We run dozens of separate tests across identity, purity, and safety. We confirm the cells are genuine mesenchymal stem cells and measure their viability. We screen for bacterial, fungal, endotoxin, and mycoplasma contamination. We run a comprehensive infectious disease panel. And we clear every batch through a 61-gene screen for genetic stability.

On treatment day, you are handed the certificates for your own specific batch. You do not have to take our word for any of it. See exactly what we test for:

Download a sample stem cell batch certificate ↓ Download a sample exosome batch certificate ↓

Cells that are alive, and ready to work.

A cell therapy is only as good as the number of living cells that actually reach you. Our cells are expanded in the lab under carefully controlled conditions that make them hardier, better prepared for the low-oxygen environment of injured tissue, and every batch is verified at a viability minimum of 98% before release, with most batches testing well above 99%. That verification is rare. Independent testing of cells from other laboratories, in both the US and Mexico, has found as little as 0 to 20% of the cells still alive on arrival, with the dead fraction adding to inflammation rather than healing. Knowing the cells you receive are alive, quantified, and documented is the difference between hoping a therapy works and knowing you have given your body the most rigorously tested option available.

FAQ’s

You’ve got questions. We’ve got answers

Honest answers about how SOMA works and what to expect.

Are SOMA’s stem cells from embryos?

No. SOMA works exclusively with ethically sourced mesenchymal stem cells from healthy, screened donors. Every cell line is processed in our ISO Class 6 GMP laboratory.

Is traveling to Mexico for treatment safe?

Treatment takes place at Del Prado Medical Tower, a COFEPRIS-regulated private hospital in Tijuana. Our team coordinates your travel, stay, and care, and on treatment day you receive the printed viability and purity results for the exact cells you will receive before any procedure begins.

Is stem cell therapy legal and regulated?

Yes. Mexico was the first country to write a legal framework for therapeutic stem cell use, and our Medical Director helped shape it. Treatment operates under COFEPRIS regulatory oversight.

How much does treatment cost?

Cost depends on your condition and your protocol. Your free consultation includes a clear breakdown, with no hidden fees and no obligation.

How do I know if I’m a candidate?

Start with our two-minute assessment or a free call. We review your medical history and give you an honest answer on whether SOMA is right for you.

Does insurance cover stem cell therapy?

Most plans do not yet cover regenerative stem cell therapy. We offer clear pricing and financing options.

Explore if SOMA is right for your health journey

Take the two-minute quiz Speak with our team
human® Peptides

Join the waitlist

Be first to know when our peptide line opens. No spam — just one note when it’s ready.

By joining you agree to receive a single launch notification.